COVID-19 and the impact on the clinical trial space

Clinical trials for therapeutic areas outside of COVID-19 are experiencing disruptions and delays as social distancing measures and travel restrictions are implemented across the world. Many sectors of the industry are also shifting R&D priorities towards finding new vaccines and treatments for COVID-19 at the expense of other indications. However, the biopharmaceutical industry is compelled to maintain its momentum in R&D in order to bring safe and effective therapies to market while protecting investments already made by companies.